Research programme: CD26 antigen antagonists - Shanghai Hengrui Pharmaceuticals

Drug Profile

Research programme: CD26 antigen antagonists - Shanghai Hengrui Pharmaceuticals

Alternative Names: Azabicyclo octane derivatives - Shanghai Hengrui; Dipeptidyl peptidase IV inhibitors - Shanghai Hengrui

Latest Information Update: 16 Jul 2016

Price : $50

At a glance

  • Originator Shanghai Hengrui Pharmaceutical
  • Class Cyclopentanes; Heterocyclic bicyclo compounds; Nitriles; Pyrrolidines; Small molecules
  • Mechanism of Action CD26 antigen inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Type 2 diabetes mellitus

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Type-2-diabetes-mellitus in China (PO)
  • 21 Aug 2008 Pharmacokinetics and pharmacodynamics data from a Preclinical trial in Type-2 diabetes mellitus presented at the 236th American Chemical Society National Meeting (236th-ACS-2008)
  • 10 Apr 2008 Preclinical trials in Type-2 diabetes mellitus in China (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top